Your session is about to expire
← Back to Search
Monoclonal Antibodies
STRO-001 for Non-Hodgkin's Lymphoma
Phase 1
Waitlist Available
Research Sponsored by Sutro Biopharma, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 24 months
Awards & highlights
Summary
This trial is testing a new drug to see if it is safe and effective. The drug will be given intravenously every 3 weeks.
Eligible Conditions
- Non-Hodgkin's Lymphoma
- Follicular Lymphoma
- Mantle Cell Lymphoma
- B-Cell Tumors
- Multiple Myeloma
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 24 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~24 months
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Part 1: Define the recommended phase 2 dose (RP2D) and maximum tolerated dose (MTD) of STRO-001
Part 1: Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability of STRO-001)
Part 2: Evaluate preliminary anti-tumor activity (NHL patients)
+1 moreSecondary outcome measures
Part 1: Assess the immunogenic potential of STRO-001
Part 1: Characterize the PK of STRO-001 by measuring the clearance (CL)
Pyruvate Kinase
+10 moreOther outcome measures
Part 1: Preliminary assessment of the anti-tumor activity of STRO-001 (NHL)
Part 1: Preliminary assessment of the anti-tumor activity of STRO-001 (multiple myeloma patients)
Trial Design
1Treatment groups
Experimental Treatment
Group I: STRO-001Experimental Treatment1 Intervention
intravenous
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
STRO-001
2018
Completed Phase 1
~70
Find a Location
Who is running the clinical trial?
Sutro Biopharma, Inc.Lead Sponsor
4 Previous Clinical Trials
950 Total Patients Enrolled
Arturo Molina, MDStudy DirectorSutro Biopharma
2 Previous Clinical Trials
218 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You have severe chronic lung disease or asthma.You have a serious heart condition that could affect your participation in the study.You have a history of serious problems with the blood vessels in your brain.You are expected to live for at least 3 more months.You have received treatment in the past that targeted CD74.You have a history of or currently have signs of brain or spinal cord involvement.Your disease has come back after treatment or it has not responded to previous treatment attempts.
Research Study Groups:
This trial has the following groups:- Group 1: STRO-001
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger